Free tool
FAERS Monitor: Cozaar
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020386 or its brand name (Cozaar, Losartan Potassium). Reports on generic versions are filed under their own applications.
Reports
80,041
Serious
47,750
60% of reports
Hospitalization
23,893
Death reported
5,554
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue5,966
- diarrhoea4,798
- nausea4,680
- drug ineffective4,371
- dyspnoea4,311
- dizziness3,963
- headache3,856
- pain3,538
- arthralgia2,885
- cough2,874
- asthenia2,815
- off label use2,665
- fall2,660
- pruritus2,620
- rash2,521
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,328 |
| 2005 | 1,648 |
| 2006 | 1,560 |
| 2007 | 1,640 |
| 2008 | 1,642 |
| 2009 | 1,764 |
| 2010 | 2,149 |
| 2011 | 3,049 |
| 2012 | 3,512 |
| 2013 | 2,189 |
| 2014 | 2,749 |
| 2015 | 3,556 |
| 2016 | 4,521 |
| 2017 | 4,434 |
| 2018 | 5,012 |
| 2019 | 5,317 |
| 2020 | 4,699 |
| 2021 | 4,614 |
| 2022 | 4,573 |
| 2023 | 4,704 |
| 2024 | 4,954 |
| 2025 | 5,724 |
| 2026 | 4,701 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,974,118 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| coughSignal | 2,874 | 2.7 | 2.6 | 3,110 |
| fallSignal | 2,660 | 2.1 | 2.0 | 1,563 |
| dizzinessSignal | 3,963 | 2.1 | 2.0 | 2,309 |
| fatigueSignal | 5,966 | 2.0 | 2.0 | 3,172 |
| dyspnoeaSignal | 4,311 | 2.0 | 2.0 | 2,226 |
| asthenia | 2,815 | 2.0 | 1.9 | 1,367 |
| diarrhoea | 4,798 | 2.0 | 1.9 | 2,310 |
| arthralgia | 2,885 | 1.8 | 1.8 | 1,098 |
| pruritus | 2,620 | 1.8 | 1.7 | 936 |
| headache | 3,856 | 1.6 | 1.6 | 937 |
| nausea | 4,680 | 1.6 | 1.5 | 963 |
| rash | 2,521 | 1.5 | 1.5 | 459 |
| pain | 3,538 | 1.5 | 1.5 | 637 |
| drug ineffective | 4,371 | 0.9 | 0.8 | 89 |
| off label use | 2,665 | 0.8 | 0.8 | 140 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.